SOUTH EASTON, Mass., May 8, 2015 /PRNewswire/ -- Pressure BioSciences, Inc. (OTCQB: PBIO) ("PBI" or the "Company"), a leader in the development and sale of broadly enabling sample preparation solutions using pressure cycling technology ("PCT")-based instruments and consumables to the worldwide life sciences industry, today announced it has been selected to present at the Cavendish Global Health Impact Forum taking place May 10^th to May 14^th in La Jolla, California.  Mr. Richard T. Schumacher, Founder and CEO of PBI will present a corporate overview on Monday afternoon, May 11, 2015.  Mr. Schumacher plans to present an update on several of PBI's key development programs, including PCT-based sample preparation methods for next generation DNA sequencing; improved extraction of chemical toxins and carcinogens from environmental samples; improved detection of DNA in forensic samples, including rape kits; and the advantages of the PCT platform in drug discovery and design, cancer detection, and in the analysis of microbial communities in soil.    

The purpose of the Forum is to help family offices and foundations develop and implement their individual pro-social impact investing, grant-giving, and philanthropy programs within health and the life sciences.  To accomplish this mission, the Forum showcases presentations and panel discussions by leading research institutions, accomplished healthcare delivery professionals, health-policy experts and private-sector companies engaged in developing innovations with the potential for transformational impact on disease prevention, diagnosis and treatment.  A unique gathering of leading family offices, Cavendish Impact Forums are hosted by leading institutions around the world and take place three times each year.  The next Forum is being co-hosted by the community of La Jolla, California including The University of California San Diego, The J. Craig Venter Institute, The Scripps Research Institute, The Sanford-Burnham Medical Research Institute, The Sanford Consortium for Regenerative Medicine, and The Institute of the Americas.

Mr. Michael Moffat, Cavendish co-founder and Chief Executive Officer explains: "The theme of our La Jolla, California Forum is a 'Celebration of Philanthropy, Impact Investing and Innovation that is Changing the World.'  With the help of our expert advisors, we conduct a global search of research institutions and private-sector companies in order to identify organizations that meet the required standard of excellence.  The quality and originality of Pressure BioSciences' research and scientific insights in the important area of sample preparation, a key part of human, animal, plant and microbial research programs worldwide, positions them to make major contributions to many important fields of the life sciences."

Mr. Richard T. Schumacher said: "We are honored to be selected to present at this unique event.  We view this invitation as further recognition of our innovative approach to the important area of sample preparation for life sciences research laboratories.  We welcome the opportunity to interact with many of world's most accomplished scientists, thought-leaders and generous philanthropic individuals and families who are all dedicated to the common cause of improving the health and lives of people around the world."

Cavendish Global consists of leading family offices and foundations from around the world with combined assets of over $190 billion who share a passion for pro-social endeavors within health and the life sciences. The Cavendish Global Health Impact Forum provides family offices with a discrete, peer-to-peer knowledge expansion and relationship building environment, combined with the information and educational resources required by foundations actively seeking to accelerate technological innovation and health access through sustainable philanthropy, grant-making and impact investing.  The Forum is also an opportunity for family offices to champion and share information on projects and organizations, which they are passionate about with other family offices from around the world.

About Pressure BioSciences, Inc.   
Pressure BioSciences, Inc. ("PBI") (OTCQB: PBIO) develops, markets, and sells proprietary laboratory instrumentation and associated consumables to the estimated $6 billion life sciences sample preparation market. Our products are based on the unique properties of both constant (i.e., static) and alternating (i.e., pressure cycling technology, or PCT) hydrostatic pressure. PCT is a patented enabling technology platform that uses alternating cycles of hydrostatic pressure between ambient and ultra-high levels to safely and reproducibly control bio-molecular interactions. To date, we have installed over 250 PCT systems in approximately 160 sites worldwide. There are over 100 publications citing the advantages of the PCT platform over competitive methods, many from key opinion leaders. Our primary application development and sales efforts are in the biomarker discovery and forensics areas. Customers also use our products in other areas, such as drug discovery & design, bio-therapeutics characterization, soil & plant biology, vaccine development, histology, and forensic applications.      

More information: www.pressurebiosciences.com.   
Please visit us on Facebook, LinkedIn, and Twitter

About Cavendish Global     
Cavendish Global provides family offices and their foundations with a discrete, peer-to-peer knowledge expansion and relationship building environment, combined with the innovative resources required to help develop and implement their individual pro-social impact investment and philanthropy programs within health and the life sciences. Cavendish Global provides family offices with a number of innovative resources, which includes Cavendish Impact Forums.  A unique gathering of leading family offices, Cavendish Impact Forums take place three times each year; the next Forum is being co-hosted at leading research institutions of the community of La Jolla, California including The University of California San Diego, The J. Craig Venter Institute, The Scripps Research Institute, The Sanford-Burnham Medical Research Institute, The Sanford Consortium for Regenerative Medicine, and The Institute of the Americas.

More information:  alex.charlton@cavendish.com.   
http://cavendishglobal.com

Forward Looking Statements   
Statements contained in this press release regarding PBI's intentions, hopes, beliefs, expectations, or predictions of the future are "forward-looking'' statements within the meaning of the Private Securities Litigation Reform Act of 1995. These statements are based upon the Company's current expectations, forecasts, and assumptions that are subject to risks, uncertainties, and other factors that could cause actual outcomes and results to differ materially from those indicated by these forward-looking statements. These risks, uncertainties, and other factors include, but are not limited to, the risks and uncertainties discussed under the heading "Risk Factors" in the Company's Annual Report on Form 10-K for the year ended December 31, 2014, and other reports filed by the Company from time to time with the SEC. The Company undertakes no obligation to update any of the information included in this release, except as otherwise required by law.

To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/pressure-biosciences-selected-to-present-at-cavendish-global-health-impact-forum-300080155.html

SOURCE Pressure BioSciences, Inc.